APPLICATION
ANDA211160
TYPE
ANDA
ORIGINAL APPROVAL
2020-12-09
LATEST ACTION
2025-07-21
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription
Products
FOSAPREPITANT DIMEGLUMINEPrescription
FOSAPREPITANT DIMEGLUMINE EQ 150MG BASE/VIAL · POWDER · INTRAVENOUS
Approval history
2025-07-21Labeling · Supplement 6 · standardAP
2025-07-21Labeling · Supplement 1 · standardAP
2020-12-09UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.